Characterization of methicillin-resistant Staphylococcus aureus associated with nosocomial infections in the University Hospital, Kuala Lumpur

1992 ◽  
Vol 21 (1) ◽  
pp. 15-28 ◽  
Author(s):  
Y.A. Hanifah ◽  
K. Hiramatsu ◽  
T. Yokota
2004 ◽  
Vol 48 (4) ◽  
pp. 1361-1364 ◽  
Author(s):  
Po-Ren Hsueh ◽  
Lee-Jene Teng ◽  
Wen-Hwei Chen ◽  
Huei-Ju Pan ◽  
Mei-Lin Chen ◽  
...  

ABSTRACT A rapid emergence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection (from 26.3% in 1986 to 77% in 2001) was found. The susceptibility of 200 nonduplicate blood isolates of MRSA and 100 MRSA isolates causing refractory bacteremia to 22 antimicrobial agents disclosed that glycopeptides, quinupristin-dalfopristin, and linezolid remained the most active agents.


2011 ◽  
Vol 56 (3) ◽  
pp. 1258-1264 ◽  
Author(s):  
Ilker Uçkay ◽  
Louis Bernard ◽  
Marta Buzzi ◽  
Stephan Harbarth ◽  
Patrice François ◽  
...  

ABSTRACTReduced susceptibility to glycopeptides in methicillin-resistantStaphylococcus aureus(MRSA) clinical isolates is considered a risk factor for failure of glycopeptide therapy. We compared the prevalences of MRSA isolates with reduced glycopeptide susceptibility in patients with versus without persistent or recurrent MRSA bloodstream infections. A retrospective cohort study at the University Hospital of Geneva identified 27 patients with persistent or recurrent clonally related MRSA bacteremic episodes over an 8-year period, which included 208 consecutive nosocomial MRSA bacteremic episodes. Vancomycin and teicoplanin MICs were determined by a modified macrodilution assay allowing improved detection of glycopeptide-intermediate MRSA isolates (GISA), characterized by elevated teicoplanin or/and vancomycin MICs (≥4 μg/ml). For 16 patients (59%), their pretherapy and/or posttherapy MRSA isolates showed elevated teicoplanin MICs, among which 10 (37%) concomitantly displayed elevated vancomycin MICs. In contrast, 11 other patients (41%) were persistently or recurrently infected with non-GISA isolates. In comparison, only 39 (22%) of 181 single isolates from patients with no microbiological evidence of persistent or recurrent infections showed elevated teicoplanin MICs, among which 14 (8%) concomitantly displayed elevated vancomycin MICs. Clinical, microbiological, and pharmacokinetic variables for patients persistently or recurrently infected with GISA or non-GISA isolates were similar. Bacteremic patients with a poor response to glycopeptide therapy had a 2.8-fold- and 4.8-fold-higher rates of MRSA isolates displaying elevated teicoplanin and vancomycin MICs, respectively, than patients with single isolates (P< 0.0001). Detection of elevated teicoplanin MICs may help to predict a poor response to glycopeptide therapy in MRSA bacteremic patients.


2019 ◽  
Vol 2 (4) ◽  
pp. 3575-3584
Author(s):  
Morgana Maria de Oliveira Barboza ◽  
José Christian Guimarães Barreto ◽  
Ana Luiza Ribeiro Aguiar ◽  
Mariana Souza Bezerra Holanda ◽  
André Jhonathan Dantas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document